MRKR
Marker Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.18
−4.84%Year over year
Reported trailing growth
- Revenue
- -77.1%
- EBITDA
- +15.1%
- EBIT
- +29.2%
- EPS
- +65.0%
- Free cash flow
- +10.4%
- Operating cash flow
- +10.4%
Forward estimates
Based on analyst estimates
- Revenue
- +324.2%
- EBITDA
- -76.0%
- EPS
- -68.1%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- -16.4%
- EBIT
- -15.9%
- Net income
- -13.3%
- EPS
- +33.6%
- Free cash flow
- -10.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026